Literature DB >> 11163666

Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge.

M Mata1, Z J Yao, A Zubair, K Syres, Y Paterson.   

Abstract

Vaccine strategies that utilize cell mediated immunity to control infection will be a necessary component of human immunodeficiency virus (HIV) vaccines. In previous studies we have shown that a Listeria monocytogenes recombinant expressing HIV-Gag elicits strong CD8+ and CD4+ T cell responses against HIV Gag in addition to its own secreted proteins. Here, we show that Lm-Gag can protect mice against a viral challenge with a recombinant vaccinia virus expressing Gag, in an antigen specific manner, and that this protection is T cell mediated. These results further support the use of L. monocytogenes as a vaccine approach for HIV through the induction of T cell immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163666     DOI: 10.1016/s0264-410x(00)00379-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Persistent Zika Virus Clinical Susceptibility despite Reduced Viral Burden in Mice with Expanded Virus-Specific CD8+ T Cells Primed by Recombinant Listeria monocytogenes.

Authors:  Ashley R Burg; John J Erickson; Lucien H Turner; Giang Pham; Jeremy M Kinder; Sing Sing Way
Journal:  J Immunol       Date:  2020-06-10       Impact factor: 5.422

2.  Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes.

Authors:  M V Rayevskaya; F R Frankel
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Schistosoma mansoni soluble egg antigens enhance T cell responses to a newly identified HIV-1 Gag H-2b epitope.

Authors:  Cac T Bui; Lisa M Shollenberger; Yvonne Paterson; Donald A Harn
Journal:  Clin Vaccine Immunol       Date:  2014-12-17

Review 4.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

5.  Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.

Authors:  Rosemary Stevens; Kristina E Howard; Sushila Nordone; MaryJo Burkhard; Gregg A Dean
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

6.  Schistosoma mansoni soluble egg antigens enhance Listeria monocytogenes vector HIV-1 vaccine induction of cytotoxic T cells.

Authors:  Cac T Bui; Lisa M Shollenberger; Yvonne Paterson; Donald A Harn
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

7.  Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.

Authors:  Matthew M Seavey; Yvonne Paterson
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05

8.  An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.

Authors:  Matthew M Seavey; Paulo C Maciag; Nada Al-Rawi; Duane Sewell; Yvonne Paterson
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

Review 9.  Listeria monocytogenes: a promising vehicle for neonatal vaccination.

Authors:  Zach Z Liang; Ashley M Sherrid; Anu Wallecha; Tobias R Kollmann
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

10.  Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.

Authors:  Hongtao Zhang; Raja Fayad; Xilin Wang; Daniel Quinn; Liang Qiao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.